share_log

復星醫藥：海外監管公告 - 上海復星醫藥（集團）股份有限公司關聯交易管理制度（2024年修訂）

FOSUN PHARMA: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

HKEX ·  Jun 26 19:50
Summary by Futu AI
上海復星醫藥（集團）股份有限公司（簡稱「復星醫藥」）於2024年6月26日發布海外監管公告，公佈了《上海復星醫藥（集團）股份有限公司關聯交易管理制度（2024年修訂）》。該修訂旨在規範公司及其附屬公司的關聯交易行為，保護公司及全體股東的合法權益。修訂內容涵蓋了關聯交易的定義、關聯方的範圍、報告與管理、以及交易的審議程序和信息披露要求。復星醫藥明確了關聯交易的合法性、必要性、合理性和公允性，並強調了上市公司獨立性的重要性。董事會下設的審計委員會將負責關聯交易的控制和日常管理，並向董事會報告工作。此外，修訂還規定了關聯交易的監督機制和罰則。公告指出，修訂後的管理制度自股東大會審議通過之日起生效。
上海復星醫藥（集團）股份有限公司（簡稱「復星醫藥」）於2024年6月26日發布海外監管公告，公佈了《上海復星醫藥（集團）股份有限公司關聯交易管理制度（2024年修訂）》。該修訂旨在規範公司及其附屬公司的關聯交易行為，保護公司及全體股東的合法權益。修訂內容涵蓋了關聯交易的定義、關聯方的範圍、報告與管理、以及交易的審議程序和信息披露要求。復星醫藥明確了關聯交易的合法性、必要性、合理性和公允性，並強調了上市公司獨立性的重要性。董事會下設的審計委員會將負責關聯交易的控制和日常管理，並向董事會報告工作。此外，修訂還規定了關聯交易的監督機制和罰則。公告指出，修訂後的管理制度自股東大會審議通過之日起生效。
On June 26, 2024, Fosun Pharma (Shanghai Fosun Pharmaceutical (Group) Co., Ltd.), released an overseas regulatory announcement, announcing the "Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Related Party Transaction Management System (Revised in 2024)". The revision aims to regulate the related party transactions of the company and its subsidiaries, protect the legitimate rights and interests of the company and all shareholders. The revision covers the definition of related party transactions, the scope of related parties, reporting and management, as well as the review procedures and information disclosure requirements for transactions. Fosun Pharma clearly states the legitimacy, necessity, reasonableness, and fairness of related party transactions and emphasizes the importance of independence of listed companies. The Audit Committee established by the board of directors will be...Show More
On June 26, 2024, Fosun Pharma (Shanghai Fosun Pharmaceutical (Group) Co., Ltd.), released an overseas regulatory announcement, announcing the "Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Related Party Transaction Management System (Revised in 2024)". The revision aims to regulate the related party transactions of the company and its subsidiaries, protect the legitimate rights and interests of the company and all shareholders. The revision covers the definition of related party transactions, the scope of related parties, reporting and management, as well as the review procedures and information disclosure requirements for transactions. Fosun Pharma clearly states the legitimacy, necessity, reasonableness, and fairness of related party transactions and emphasizes the importance of independence of listed companies. The Audit Committee established by the board of directors will be responsible for the control and daily management of related party transactions and report their work to the board of directors. In addition, the revision also provides for a supervision mechanism and penalties for related party transactions. The announcement stated that the revised management system will take effect from the date of approval by the shareholders' meeting.

This announcement is a separate document:

Doc 1

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.